Production of proteins for biopharmaceutical applications in plants;La production de protéines à usage biopharmaceutique dans les plantes

Medecine/Sciences

Volumn 17, Issue 8-9, 2001, Pages 867-877

  Faye, Loïc ^a   Landry, Nathalie ^b   Lerouge, Patrice ^a   Gomord, Véronique ^a   Vézina, Louis P ^b  

^a UNIVERSITÉ DE ROUEN   (France)

^b Medicago Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA INTERFERON; ANTIBODY; APROTININ; BETA INTERFERON; CARCINOEMBRYONIC ANTIBODY; CHOLERA TOXIN B SUBUNIT; COSMETIC; CYTOKINE; ENKEPHALIN; ERYTHROPOIETIN; ESCHERICHIA COLI ENTEROTOXIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMAGGLUTININ; HEMOGLOBIN; HIRUDIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INSULIN; LACTOFERRIN; PLASMA PROTEIN; RECOMBINANT GROWTH HORMONE; TRICHOSANTHIN; VACCINE; VIRUS ANTIGEN;

BIOTECHNOLOGY; DRUG INDUSTRY; DRUG SYNTHESIS; NONHUMAN; PHYTOCHEMISTRY; PROTEIN GLYCOSYLATION; PROTEIN SYNTHESIS; RECOMBINANT DNA TECHNOLOGY; REVIEW;

EID: 0034816990     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/2021     Document Type: Review

References (55)

1. Parmenter DL,Boothe JG, van Rooijen GJ, Yeung EC, Moloney MM. Production of biologically active hirudin in plant seeds using oleosin partitioning. Plant Mol Biol 1995; 29: 1167-80.
2. Boothe JG, Saponja JA, Parmenter DL, et al. Molecular farming in plants: oilseed as vehicles for the production of pharmaceutical proteins. Drug Dev Res 1997; 42: 172-8.
3. Sijmons PC, Dekker BM, Schrammeijer B, Verwoerd tc, van den ElzenPJ, Hoekema A. Production of correctly processed serum albumin in transgenic plants. Bio/Technology 1990; 8: 217-21.
4. Biopharmaceuticals from tobacco, Croptech. ISB News Reports 2000.
5. Zhong GY, Peterson D, Delaney DE, et al. Commercial production of aprotinin in transgenic maize seeds. Mol Breed 1999; 5: 345-56.
6. Vandekerckhove J, Damme JV, Lijsebettens MV, et al. Enkephalines produced in transgenic plants using modified 2S storage proteins. Bio/Technology 1989; 7: 929-32.
7. Dieryck W, Pagnier J, Poyart, et al. Human haemoglobin from transgenic tobacco. Nature 1997; 386: 29-30.
8. Ruggerio F, Exposito JY, Bournat P, et al. Triple helix assembly and processing of human collagen produced in transgenic tobacco plants. FEBS Lett 2000; 469: 132-6.
9. Richter LJ, Thanavala Y, Arntzen CJ, Mason HS. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol 2000; 18: 1167-71.
10. Mason HS, Haq TA, Clements JD, Arntzen CJ. Edible vaccine protects mice against Escherichia coli heat-labile cnterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine 1998; 16: 1336-43.
11. Kusnadi A, Nikplov ZL, Howard JA. Production of recombinant proteins in transgenic plants: practical considerations. Biotech Bioeng 1997; 56: 473-84.
12. Hiatt AC, Cafferkey R, Bowdish K. Production of antibodies in transgenic plants. Nature 1989; 342: 76-8.
13. Khoudi H, Laberge S, Fenillo JM, et al. Production of a diagnostic monoclonal antibody in perennial alfalfa plants. Biotech Bioeng 1999; 64: 135-43.
14. Staub JM, Garcia B, Graves J, et al. High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat Biotechnol 2000; 18: 333-8.
15. Conrad U, Fiedler U, Artsaenko O, Phillips I. High-level and stable accumulation of single-chain Fv antibodies in plant storage organs. J Plant Physiol 1998; 152: 708-11.
16. Verch T, Yusibov, V, Joprowski H. Expression and assembly of a full-lenght monoclonal antibody in plants using a plant virus vector. J Immunol 1998; 220: 69-74.
17. Stoger E, Vaquero C, Torres E, et al. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. Plant Mol Biol 2000; 42: 583-90.
18. Therapeutic proteins 1999: a seven country analysis and forecasts to 2007. Data Monitor 2000.
19. James EA, Wang C, Wang Z, et al. Production and characterization of biologically active human GM-CSF secreted by genetically modified plant cells. Prot Expr Purif 2000; 19: 131-8.
20. Goddjin OJM, Pen J. Plants as bioreactors. Trends Biotechnol 1995; 13: 379-87.
21. Cramer CL, Weissenborn DL, Oishi KK, et al. Bioproduction of human enzymes in transgenic tobacco. Ann NY Acad Sci 1996; 792: 62-71.
22. Kumagai MH, Turpen TH, Weinzettl N, et al. Rapid, high-level expression of biologically active alpha-trichosanthin in transfected plants by an RNA viral vector. Proc Natl Acad Sci USA 1993; 90: 427-30.
23. Steiner UP. Assessment of the economics of transgenic technologies for biologicals. Bayer Biotechnology, Bayer Corporation. Communication dans le cadre du congrès Production and economics of biopharmaceuticals. 13-15 janvier 2000.
24. Cabanes-Macheteau M, Fitchette-laine AC, Loutelier-Bourhis C, et al. N-Glycosylation of a mouse IgG expressed in transgenic tobacco plants. Glycobiology 1999; 9: 365-72.
25. Fitchette-Laine AC, Gomord V, Chekkafi A, Faye L. Distribution of xylosylation and fucosylation in the plant Golgi apparatus. Plant J 1994; 5: 673-82.
26. Garcia-Casado G, Sanchez-Monge R, Chrispeels MJ, Armentia A, Salcedo G, Gomez L. Role of complex asparagine-linked glycans in the allergenicity of plant glycoproteins. Glycobiology 1996; 6: 471-7.
27. Van Ree R, Cabanes-Macheteau M, Akkerdaas J, et al. b(1,2)-xylose and a(1,3)-fucose residues have a strong contribution in IgE binding to plant glycoallergens. J Biol Chem 2000; 275: 11451-8.
28. Lerouge P, Cabanes-Macheteau M, Rayon C, Fitchette-Lainé AC, Gomord V, Faye L. N-glycoprotein biosynthesis in plants: recent developments and future trends. Plant Mol Biol 1998; 38: 31-48.
29. Pagny S, Cabanes-Macheteau M, Gillikin JW, et al. Protein reading from the Golgi apparatus to the endoplasmic reticulum in plants and its minor contribution to calreticulin retention. Plant Cell 2000; 12: 739-55.
30. Navazio L, Baldan B, Mariani P, Genug GJ, Vliegenhart JFG. Primary structure of the N-linked carbohydrate chains of calreticulin from spinach leaves. Glycoconjugate J 1996; 13: 977-83.
31. Gomord V, Denmat LA, Fitchette-Lainé AC, Satiat-jeunemaitre B, Hawes C, Faye L. The C-terminal HDEL sequence is sufficient for retention of secretory proteins in the endoplasmic reticulum (ER) but promotes vacuolar targeting of proteins that escape the ER. Plant J 1997; 11: 313-25.
32. von Schaewen A, Sturm A, O'Neill J, Chrispeels MJ. Isolation of a mutant Arabidopsis plant that lacks N-acetyl glucosaminyl transferase I and is unable to synthesize Golgi-modified complex N-linked glycans. Plant Physiol 1993; 102: 1109-18.
33. Strasser R., Mucha J, Schwihla H, Altmann F, Glössl J, Steinkellner H. Molecular cloning and characterization of cDNA coding for b1,2N-acetylglusaminyltransferase I from Nicotiana tabacum. Glycobiology 1999; 9: 779-85.
34. Wenderoth I, von Schaeven A. Isolation and characterization of plant N-acetylglucosaminyltransferase I (GNT I)cDNA sequences. Functional analyses in the arabidopsis cgl mutant and in antisens plants. Plant Physiol 2000; 123: 1097-108.
35. Wee EGT, Sherrier DJ, Prime TA, Dupree P. Targeting of active sialyltransferase to the plant Golgi apparatus. Plant Cell 1998; 10: 1759-68.
36. Palacpac NQ, Yoshida S, Sakai H, et al. Stable expression of human betal,4-galacto-syltransfcrasc in plant cells modifies N-linkcd glycosylation patterns. Proc Natl Acad Sci USA 1998; 96: 4692-7.
37. Bakker H, Bardor M, Molthoff JW, et al. Galactose-extended glycans of antibodies produced by transgenic plants. Proc Natl Acad Sci USA 2001; 98: 2899-904.
38. Krebitz M, Wiedermann U, Essl D, et al. Rapid production of the major birch pollen allergen Bet v l in Nicotiana benthamiana plants and its immunological in vitro and in vivo characterization. FASEB J 2000; 14: 1279-88.
39. Arakawa T, Chong DK, Langridge WH. Efficacy of a food plant-based oral cholera toxin subunit vaccine. Nat Biotechnol 1998; 16: 292-7.
40. Tackaberry ES, Dudani AK, Prior F, et al. Development of biopharmaceuticals in plant expression systems: cloning, expression and immunological reactivity of human cytomegalovinis glycoprotein B (UL55) in seeds of transgenic tobacco. Vaccine 1999; 17: 23-1.
41. Arakawa T, Yu J, Langridge WH. Food plant-delivered cholera toxin B subunit for vaccination and immunotolerization. Adv Exp Med Biol 1999; 464: 161-78.
42. Wigdorovitz A, Carrillo C, Dus Santos MJ, et al. Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. Virology 1999; 255: 347-53.
43. Tacket CO, Mason US. A review of oral vaccination with transgenic vegetables. Microbes Infect 1999; 1: 777-83.
44. Beachy RN. Use of plant viruses for delivery of vaccine epitopes. In Engineering plant for commercial products and applications. Ann NY Acad Sci 1996; 25: 43-9.
45. Turpen TH, Reinl SJ, Charoenvit Y, Hoffman SL, Fallanne V, Grill LK. Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. Bio/Technology 1995; 13: 53-7.
46. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 2000; 182: 302-5.
47. McGarvey PB, Hammond J, Dienelt MM, et al. Expression of the rabies virus glycoprotein in transgenic tomatoes. Bio/Technology 1995; 13: 1484-7.
48. Ma SW, Zhao DL, Yin ZQ, et al. Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nat Med 1997; 3: 793-6.
49. Robinson A. Harvesting blood proteins from grain. CMAJ 1995; 153: 427-9.
50. Edelbaum O, Stein D, Holland N, et al. Expression of active human interferon-beta in transgenic plants. Interferon Res 1992; 12: 449-53.
51. De Zoeten GA, Penswick JR, Horisberger MA, AhI P, Schnitze M, Hohn T. The expression, localization, and effect of a human interferon in plants. Virology 1989; 172: 213-22.
52. Matsumoto S, Ikura K, Ueda M, Sasaki R. Characterization of a human glycoprotein (erythropoietin) produced in cultured tobacco cells. Plant Mol Biol 1995; 27: 1163-72.
53. Hamamoto H, Sugiyama Y, Nakagawa N, et al. A new tobacco mosaic virus vector and its use for the systematic production of angiotensin-I-converting enzyme inhibitor in transgenic tobacco and tomatoe. Bio/Technology 1993; 11: 930-2.
54. Cramer C, Boothe JG, Oishi KK. Transgenic plants for therapeutic proteins: linking upstream and downstream strategies. Curr Tob Microbiol Immunol 1999; 240: 95-118.
55. Salmon V, Legrand D, Slomianny MC, et al. Production of human lactoferin in transcenic tobacco plants. Prot Exbr Purif 1998; 13: 127-35.